SCHEMBL2004634

SCHEMBL2004634

Cc1cc2c(cc1C)C1(SCCS1)C(=O)N2

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.66
CYP2C19 P33261 2/20 0.66
POLB P06746 2/20 0.66
CYP3A4 P08684 1/20 0.66
MAPT P10636 2/20 0.57
KMT2A Q03164 2/20 0.36
PDE4A P27815 1/20 0.35
PDE4B Q07343 1/20 0.35
PDE4C Q08493 1/20 0.35
PDE4D Q08499 1/20 0.35
PDE3B Q13370 1/20 0.35
PDE3A Q14432 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.33
MEN1 O00255 1/20 0.32
LMNA P02545 1/20 0.32
XBP1 P17861 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MAPK14 Q16539 1/20 0.31
AKR1B1 P15121 1/20 0.31
HTT P42858 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2006345 0.79 CYP1A2 (1.00) CYP1A2CYP2C19POLBCYP3A4MAPT
SCHEMBL2265427 0.68 KMT2A (0.38) CYP1A2CYP2C19POLBCYP3A4MAPT
SCHEMBL2265422 0.68 KMT2A (0.38) CYP1A2CYP2C19POLBCYP3A4MAPT
SCHEMBL2267056 0.68 KMT2A (0.38) CYP1A2CYP2C19POLBCYP3A4MAPT
SCHEMBL2006943 0.66 CYP1A2 (0.61) CYP1A2CYP2C19POLBCYP3A4MAPT
SCHEMBL31219578 0.62 BCHE (0.47) PDE4APDE4BPDE4CPDE4DPDE3B
SCHEMBL29622128 0.61 PDE4A (0.43) CYP1A2CYP2C19PDE4APDE4BPDE4C
SCHEMBL5757053 0.58 ATAD2 (0.46) MAPTKMT2APDE4APDE4BPDE4C
SCHEMBL8853758 0.58 LMNA (0.54) CYP2C19POLBMAPTKMT2ASMN1; SMN2
SCHEMBL5975963 0.58 PGR (0.49) MAPK14AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US claimed
US-7964593-B2 Indolone-acetamide derivatives, processes for preparing them and their uses UCB PHARMA, S.A. (BE) 2011-06-21 US disclosed
EP-1620399-B1 INDOLONE-ACETAMIDE DERIVATIVES, PROCESSES FOR PREPARING THEM AND THEIR USES UCB PHARMA SA (BE) 2010-09-22 EP disclosed
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses UCB PHARMA, S.A. (BE) 2010-03-18 US disclosed
US-7645887-B2 2-(5-iodo-2-oxo-2,3-dihydro-1H-indol-1-yl)acetamide; epilepsy, epileptogenesis, seizure disorders and convulsion; 2-(5-chloro-2-oxo-2,3-dhydro-1H-indol-1-yl)-N-[6-(hydroxymethyl)cyclohex-3-en-1-yl]acetamide UCB PHARMA, S.A. (BE) 2010-01-12 US disclosed
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses UCB, S.A. (BE) 2007-02-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069375-A1 Indolone-Acetamide Derivatives, Processes for Preparing Them and Their Uses AANAT, TPH2, CYP1A2 CYP1A2 3/4885CYP2C19 69/4885POLB 3404/4885
US-20070043038-A1 Indolone-acetamide derivatives, processes for preparing them and their uses AANAT, TPH2, CYP1A2 CYP1A2 3/4885CYP2C19 69/4885POLB 3404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.